Press Releases

Immunomic Therapeutics Appoints Recognized Immuno-Oncology Expert, Dr. Richard Ambinder, to its Scientific Advisory Board September 10, 2018 06:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately

January 23, 2018 11:24 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Tomorrow, Immunomic Therapeutics, Inc. Senior Director of Corporate Development Sia Anagnostou will present at Phacilitate’s Immuno-Oncology Frontiers World in Miami.

December 13, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, is pleased to welcome Drew Pardoll, MD, Ph.D., Director of

Cancer Vaccination Approach Incorporates Immunomic Therapeutics' LAMP-Vax Technology with CMV Technology November 22, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Last week results from a study conducted by investigators

Presentation to Examine the Potential of LAMP Enhancing Antitumor Immunity November 13, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Tomorrow, Immunomic Therapeutics, Inc. scientist, Dr. Pratima Sinha, will present

October 11, 2017 07:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company is proud to announce a travel fund for patients enrolled

July 31, 2017 07:30 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company is pleased to welcome a new oncology advisor, Duke University’s

Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions Due to Peanut Allergy   TOKYO, Dec. 20, 2016 /PRNewswire/ -- Astellas Pharma Inc.

June 12, 2017 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Sia Anagnostou, Senior Director of Corporate Development at Immunomic Therapeutics, Inc., will participate in a BioPharma Dealmakers webcast, sponsored in

Bill Hearl and Greg Simon to Examine Lessons from the Cancer Moonshot Initiative    May 23, 2017 08:00 AM Eastern Daylight Time WASHINGTON--(BUSINESS WIRE)-- Tomorrow, IVY and Immunomic Therapeutics, Inc. (ITI)

May 22, 2017 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Tomorrow, Immunomic Therapeutics, Inc. (ITI) Senior Vice President of Research and Development Teri Heiland, Ph.D., will present on DNA vaccines

Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting Cytomegalovirus (CMV)   Immunomic exclusively licensed patent portfolio from Annias Immunotherapeutics for use in combination with Immunomic’s investigational